Product Description: TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers[1][2].
Applications: Cancer-programmed cell death
Formula: C28H36N6O2S
References: [1]Briggs K, et al. TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors[J]. Cancer Research, 2023, 83(7_Supplement): 4970-4970./[2]Kevin M Cottrell, et al. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers. Patent WO2022026892A1.
CAS Number: 2760483-96-1
Molecular Weight: 520.69
Compound Purity: 99.91
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Histone Methyltransferase
English
Deutsch
